Research Assistant/Research Associate (Computational Biologist) (Fixed Term)

at  University of Cambridge

Cambridge, England, United Kingdom -

Start DateExpiry DateSalaryPosted OnExperienceSkillsTelecommuteSponsor Visa
Immediate11 Jul, 2024GBP 33966 Annual28 Jun, 2024N/AGood communication skillsNoNo
Add to Wishlist Apply All Jobs
Required Visa Status:
CitizenGC
US CitizenStudent Visa
H1BCPT
OPTH4 Spouse of H1B
GC Green Card
Employment Type:
Full TimePart Time
PermanentIndependent - 1099
Contract – W2C2H Independent
C2H W2Contract – Corp 2 Corp
Contract to Hire – Corp 2 Corp

Description:

DO YOU WANT YOUR RESEARCH TO TRANSLATE INTO THE CLINIC?

This is an exciting opportunity to join a cutting-edge research group at the University of Cambridge. The Fitzgerald group pioneered the use of a capsule sponge medical device to screen for the precancerous condition Barrett’s Oesophagus. This condition can progress to oesophageal adenocarcinoma which has a staggeringly poor 5-year survival rate of less than 5%. This project seeks to apply state-of-the-art computational approaches to whole genome sequencing data to identify pre-cancerous and cancerous changes. In the future this work may contribute towards a national screening program for oesophageal disease.

PHD (OR CLOSE TO OBTAINING) QUALIFICATION - A POST HOLDER WILL BE APPOINTED TO RESEARCH ASSOCIATE, GRADE 7

Fixed-term: The funds for this post are available for 12 months in the first instance.
Click the ‘Apply’ button below to register an account with our recruitment system (if you have not already) and apply online.

Responsibilities:

PURPOSE OF THE ROLE

The Early Cancer Institute at the University of Cambridge (https://www.earlycancer.cam.ac.uk/) is the UK’s only institute dedicated to Early Cancer; a world-leading centre for research into the development, early detection and interception of cancer. The Fitzgerald Group have pioneered non-endoscopic tests for the early diagnosis of oesophageal cancer and a large multi-centre definitive screening trial BEST4 is starting recruitment in late 2024. The purpose of this role is to further refine diagnostic biomarkers to ensure scalability of capsule sponge screening tests and improve risk stratification.

KEY RESPONSIBILITIES

  • To analyse shallow-depth whole-genome-sequencing data from capsule sponge samples
  • To identify features of the data that could act as biomarkers to diagnose disease progression
  • Actively participate in the Fitzgerald Group and more broadly in the Early Cancer Institute to promote a friendly, kind and inclusive research culture pursuing research excellence
  • Publish research work in appropriate journals and disseminate research findings by presenting at national and international conferences and using other appropriate media
  • Communicate complex and conceptual ideas to those with limited knowledge and understanding as well as to peers using high level skills and a range of media
  • Continually update and expand knowledge in early detection and engage in continuing professional development.


REQUIREMENT SUMMARY

Min:N/AMax:5.0 year(s)

Information Technology/IT

Pharma / Biotech / Healthcare / Medical / R&D

Software Engineering

Phd

Proficient

1

Cambridge, United Kingdom